annual EBITDA:
$17.12B+$3.70B(+27.56%)Summary
- As of today (April 13, 2025), AZN annual EBITDA is $17.12 billion, with the most recent change of +$3.70 billion (+27.56%) on December 31, 2024.
- During the last 3 years, AZN annual EBITDA has risen by +$12.01 billion (+234.85%).
- AZN annual EBITDA is now at all-time high.
Performance
AZN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$4.43B+$330.00M(+8.04%)Summary
- As of today (April 13, 2025), AZN quarterly EBITDA is $4.43 billion, with the most recent change of +$330.00 million (+8.04%) on December 31, 2024.
- Over the past year, AZN quarterly EBITDA has stayed the same.
- AZN quarterly EBITDA is now -10.61% below its all-time high of $4.96 billion, reached on September 30, 2011.
Performance
AZN quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$17.12B+$2.25B(+15.15%)Summary
- As of today (April 13, 2025), AZN TTM EBITDA is $17.12 billion, with the most recent change of +$2.25 billion (+15.15%) on December 31, 2024.
- Over the past year, AZN TTM EBITDA has stayed the same.
- AZN TTM EBITDA is now at all-time high.
Performance
AZN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AZN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +27.6% | 0.0% | 0.0% |
| 3 y3 years | +234.8% | +131.4% | +248.6% |
| 5 y5 years | +155.1% | +131.4% | +248.6% |
AZN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +234.8% | -0.8% | +131.4% | at high | +253.8% |
| 5 y | 5-year | at high | +234.8% | -0.8% | +1467.9% | at high | +253.8% |
| alltime | all time | at high | +2391.9% | -10.6% | +191.7% | at high | +4158.9% |
AstraZeneca EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $17.12B(+27.6%) | $4.43B(+8.0%) | $17.12B(+15.2%) |
| Sep 2024 | - | $4.10B(-0.4%) | $14.87B(+5.5%) |
| Jun 2024 | - | $4.12B(-7.8%) | $14.09B(+2.4%) |
| Mar 2024 | - | $4.47B(+105.0%) | $13.77B(+2.5%) |
| Dec 2023 | $13.42B(+47.7%) | $2.18B(-34.5%) | $13.43B(-1.4%) |
| Sep 2023 | - | $3.33B(-12.4%) | $13.63B(+5.7%) |
| Jun 2023 | - | $3.79B(-8.1%) | $12.89B(+17.1%) |
| Mar 2023 | - | $4.13B(+73.8%) | $11.02B(+21.3%) |
| Dec 2022 | $9.09B(+77.7%) | $2.38B(-8.4%) | $9.08B(+42.3%) |
| Sep 2022 | - | $2.60B(+35.5%) | $6.38B(+30.0%) |
| Jun 2022 | - | $1.92B(-12.9%) | $4.91B(+1.5%) |
| Mar 2022 | - | $2.20B(-778.4%) | $4.84B(-9.5%) |
| Dec 2021 | $5.11B(-36.8%) | -$324.00M(-128.9%) | $5.35B(-30.3%) |
| Sep 2021 | - | $1.12B(-39.1%) | $7.67B(-10.0%) |
| Jun 2021 | - | $1.84B(-31.9%) | $8.53B(-1.8%) |
| Mar 2021 | - | $2.71B(+35.5%) | $8.68B(+7.4%) |
| Dec 2020 | $8.08B(+20.4%) | $2.00B(+1.0%) | $8.08B(-2.5%) |
| Sep 2020 | - | $1.98B(-1.1%) | $8.29B(+6.4%) |
| Jun 2020 | - | $2.00B(-5.1%) | $7.79B(+11.0%) |
| Mar 2020 | - | $2.11B(-4.4%) | $7.02B(+4.6%) |
| Dec 2019 | $6.71B(-5.6%) | $2.20B(+49.1%) | $6.71B(-6.6%) |
| Sep 2019 | - | $1.48B(+20.3%) | $7.18B(-0.8%) |
| Jun 2019 | - | $1.23B(-31.8%) | $7.25B(-3.2%) |
| Mar 2019 | - | $1.80B(-32.7%) | $7.49B(+5.3%) |
| Dec 2018 | $7.11B(+7.4%) | $2.68B(+73.9%) | $7.11B(+16.4%) |
| Sep 2018 | - | $1.54B(+4.6%) | $6.11B(-4.4%) |
| Jun 2018 | - | $1.47B(+3.2%) | $6.39B(-1.3%) |
| Mar 2018 | - | $1.43B(-14.9%) | $6.48B(-2.3%) |
| Dec 2017 | $6.62B(-9.0%) | $1.68B(-7.9%) | $6.63B(-17.9%) |
| Sep 2017 | - | $1.82B(+16.9%) | $8.07B(+2.2%) |
| Jun 2017 | - | $1.56B(-1.5%) | $7.90B(+9.1%) |
| Mar 2017 | - | $1.58B(-49.3%) | $7.24B(-0.5%) |
| Dec 2016 | $7.28B(+4.5%) | $3.12B(+89.9%) | $7.28B(+22.7%) |
| Sep 2016 | - | $1.64B(+82.6%) | $5.93B(-1.8%) |
| Jun 2016 | - | $899.00M(-44.4%) | $6.04B(-11.1%) |
| Mar 2016 | - | $1.62B(-8.9%) | $6.79B(-2.5%) |
| Dec 2015 | $6.96B(+26.8%) | $1.77B(+1.5%) | $6.96B(+18.2%) |
| Sep 2015 | - | $1.75B(+5.9%) | $5.89B(+6.1%) |
| Jun 2015 | - | $1.65B(-7.7%) | $5.55B(-2.9%) |
| Mar 2015 | - | $1.79B(+155.1%) | $5.71B(+4.1%) |
| Dec 2014 | $5.49B(-34.2%) | $701.00M(-50.2%) | $5.49B(-19.4%) |
| Sep 2014 | - | $1.41B(-22.5%) | $6.81B(-9.3%) |
| Jun 2014 | - | $1.82B(+16.3%) | $7.51B(-4.2%) |
| Mar 2014 | - | $1.56B(-22.8%) | $7.84B(-6.1%) |
| Dec 2013 | $8.34B(-21.9%) | $2.02B(-4.0%) | $8.35B(-7.7%) |
| Sep 2013 | - | $2.11B(-1.8%) | $9.04B(-8.1%) |
| Jun 2013 | - | $2.15B(+3.7%) | $9.84B(-2.4%) |
| Mar 2013 | - | $2.07B(-23.8%) | $10.09B(-5.6%) |
| Dec 2012 | $10.68B(-30.6%) | $2.72B(-6.6%) | $10.68B(-0.3%) |
| Sep 2012 | - | $2.91B(+21.8%) | $10.72B(-16.0%) |
| Jun 2012 | - | $2.39B(-10.4%) | $12.77B(-8.7%) |
| Mar 2012 | - | $2.67B(-3.2%) | $13.99B(-9.1%) |
| Dec 2011 | $15.39B(+4.4%) | $2.75B(-44.5%) | $15.39B(-6.6%) |
| Sep 2011 | - | $4.96B(+37.3%) | $16.48B(+12.5%) |
| Jun 2011 | - | $3.61B(-11.1%) | $14.65B(+0.1%) |
| Mar 2011 | - | $4.06B(+5.6%) | $14.63B(-0.8%) |
| Dec 2010 | $14.74B(+5.7%) | $3.85B(+22.9%) | $14.75B(+5.4%) |
| Sep 2010 | - | $3.13B(-12.8%) | $13.98B(-4.5%) |
| Jun 2010 | - | $3.59B(-14.0%) | $14.64B(+1.3%) |
| Mar 2010 | - | $4.18B(+35.4%) | $14.46B(+3.7%) |
| Dec 2009 | $13.95B(+10.5%) | $3.08B(-18.6%) | $13.95B(+0.4%) |
| Sep 2009 | - | $3.79B(+11.2%) | $13.90B(+3.8%) |
| Jun 2009 | - | $3.41B(-6.9%) | $13.39B(+2.5%) |
| Mar 2009 | - | $3.66B(+20.6%) | $13.06B(+3.5%) |
| Dec 2008 | $12.62B | $3.04B(-7.6%) | $12.62B(+11.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2008 | - | $3.29B(+6.8%) | $11.36B(+4.4%) |
| Jun 2008 | - | $3.08B(-4.3%) | $10.88B(+4.8%) |
| Mar 2008 | - | $3.22B(+80.9%) | $10.38B(+4.3%) |
| Dec 2007 | $9.95B(+4.1%) | $1.78B(-36.6%) | $9.95B(-0.3%) |
| Sep 2007 | - | $2.80B(+8.6%) | $9.98B(+1.5%) |
| Jun 2007 | - | $2.58B(-7.4%) | $9.83B(-2.5%) |
| Mar 2007 | - | $2.79B(+54.0%) | $10.09B(+5.5%) |
| Dec 2006 | $9.56B(+22.1%) | $1.81B(-31.9%) | $9.56B(+2.8%) |
| Sep 2006 | - | $2.66B(-6.4%) | $9.30B(+2.6%) |
| Jun 2006 | - | $2.84B(+25.6%) | $9.06B(+10.4%) |
| Mar 2006 | - | $2.26B(+46.1%) | $8.21B(+4.8%) |
| Dec 2005 | $7.83B(+34.6%) | $1.55B(-36.1%) | $7.83B(-1.2%) |
| Sep 2005 | - | $2.42B(+21.9%) | $7.93B(+13.7%) |
| Jun 2005 | - | $1.98B(+5.5%) | $6.97B(+9.9%) |
| Mar 2005 | - | $1.88B(+14.5%) | $6.34B(+8.5%) |
| Dec 2004 | $5.82B(+9.7%) | $1.64B(+12.3%) | $5.85B(+10.9%) |
| Sep 2004 | - | $1.46B(+8.0%) | $5.27B(-2.4%) |
| Jun 2004 | - | $1.35B(-2.2%) | $5.40B(+5.6%) |
| Mar 2004 | - | $1.39B(+29.9%) | $5.12B(-3.4%) |
| Dec 2003 | $5.30B(+6.7%) | $1.07B(-33.1%) | $5.30B(+1.9%) |
| Sep 2003 | - | $1.59B(+48.9%) | $5.20B(+8.7%) |
| Jun 2003 | - | $1.07B(-31.7%) | $4.78B(-4.5%) |
| Mar 2003 | - | $1.57B(+61.8%) | $5.01B(+0.9%) |
| Dec 2002 | $4.97B(-1.0%) | $968.80M(-17.7%) | $4.97B(-6.6%) |
| Sep 2002 | - | $1.18B(-9.2%) | $5.31B(-0.9%) |
| Jun 2002 | - | $1.30B(-15.0%) | $5.36B(+2.7%) |
| Mar 2002 | - | $1.52B(+15.7%) | $5.22B(+4.4%) |
| Dec 2001 | $5.02B(+2.1%) | $1.32B(+7.6%) | $5.00B(+0.5%) |
| Sep 2001 | - | $1.22B(+6.2%) | $4.97B(+0.7%) |
| Jun 2001 | - | $1.15B(-11.5%) | $4.93B(-1.7%) |
| Mar 2001 | - | $1.30B(+0.9%) | $5.02B(+2.2%) |
| Dec 2000 | $4.91B(+9.2%) | $1.29B(+8.7%) | $4.91B(+11.3%) |
| Sep 2000 | - | $1.19B(-4.3%) | $4.41B(+0.4%) |
| Jun 2000 | - | $1.24B(+3.9%) | $4.39B(-0.7%) |
| Mar 2000 | - | $1.19B(+50.7%) | $4.42B(-42.9%) |
| Dec 1999 | $4.50B(+38.5%) | $792.00M(-32.2%) | $7.75B(+264.3%) |
| Sep 1999 | - | $1.17B(-7.9%) | $2.13B(-35.3%) |
| Jun 1999 | - | $1.27B(-71.9%) | $3.29B(+13.8%) |
| Mar 1999 | - | $4.52B(-193.6%) | $2.89B(+268.0%) |
| Dec 1998 | $3.25B(+44.7%) | -$4.83B(-307.3%) | $785.10M(-34.9%) |
| Sep 1998 | - | $2.33B(+168.1%) | $1.21B(+23.7%) |
| Jun 1998 | - | $869.00M(-64.1%) | $975.55M(-59.2%) |
| Mar 1998 | - | $2.42B(-154.8%) | $2.39B(+5.9%) |
| Dec 1997 | $2.24B(+4.4%) | -$4.41B(-310.1%) | $2.26B(-40.9%) |
| Sep 1997 | - | $2.10B(-8.1%) | $3.82B(-5.3%) |
| Jun 1997 | - | $2.28B(0.0%) | $4.03B(+0.1%) |
| Mar 1997 | - | $2.28B(-180.2%) | $4.03B(+0.1%) |
| Dec 1996 | $2.15B(+59.1%) | -$2.85B(-223.1%) | $4.02B(+89.9%) |
| Sep 1996 | - | $2.31B(+1.5%) | $2.12B(+21.8%) |
| Jun 1996 | - | $2.28B(0.0%) | $1.74B(-1184.3%) |
| Mar 1996 | - | $2.28B(-147.9%) | -$160.41M(-62.0%) |
| Dec 1995 | $1.35B(-8.5%) | -$4.75B(-345.6%) | -$421.81M(-240.2%) |
| Sep 1995 | - | $1.94B(+411.0%) | $300.94M(+153.4%) |
| Jun 1995 | - | $378.70M(-81.2%) | $118.74M(-92.5%) |
| Mar 1995 | - | $2.02B(-150.1%) | $1.58B(+12.9%) |
| Dec 1994 | $1.48B(+6.0%) | -$4.03B(-329.9%) | $1.40B(-8.8%) |
| Sep 1994 | - | $1.75B(-4.6%) | $1.53B(+16.4%) |
| Jun 1994 | - | $1.84B(0.0%) | $1.32B(+7.2%) |
| Mar 1994 | - | $1.84B(-147.2%) | $1.23B(+7.8%) |
| Dec 1993 | $1.39B(+102.8%) | -$3.90B(-353.4%) | $1.14B(-77.4%) |
| Sep 1993 | - | $1.54B(-12.1%) | $5.03B(+44.0%) |
| Jun 1993 | - | $1.75B(0.0%) | $3.50B(+100.0%) |
| Mar 1993 | - | $1.75B | $1.75B |
| Dec 1992 | $687.06M(-59.1%) | - | - |
| Dec 1991 | $1.68B(+22.2%) | - | - |
| Dec 1990 | $1.37B | - | - |
FAQ
- What is AstraZeneca annual EBITDA?
- What is the all time high annual EBITDA for AstraZeneca?
- What is AstraZeneca annual EBITDA year-on-year change?
- What is AstraZeneca quarterly EBITDA?
- What is the all time high quarterly EBITDA for AstraZeneca?
- What is AstraZeneca quarterly EBITDA year-on-year change?
- What is AstraZeneca TTM EBITDA?
- What is the all time high TTM EBITDA for AstraZeneca?
- What is AstraZeneca TTM EBITDA year-on-year change?
What is AstraZeneca annual EBITDA?
The current annual EBITDA of AZN is $17.12B
What is the all time high annual EBITDA for AstraZeneca?
AstraZeneca all-time high annual EBITDA is $17.12B
What is AstraZeneca annual EBITDA year-on-year change?
Over the past year, AZN annual EBITDA has changed by +$3.70B (+27.56%)
What is AstraZeneca quarterly EBITDA?
The current quarterly EBITDA of AZN is $4.43B
What is the all time high quarterly EBITDA for AstraZeneca?
AstraZeneca all-time high quarterly EBITDA is $4.96B
What is AstraZeneca quarterly EBITDA year-on-year change?
Over the past year, AZN quarterly EBITDA has changed by $0.00 (0.00%)
What is AstraZeneca TTM EBITDA?
The current TTM EBITDA of AZN is $17.12B
What is the all time high TTM EBITDA for AstraZeneca?
AstraZeneca all-time high TTM EBITDA is $17.12B
What is AstraZeneca TTM EBITDA year-on-year change?
Over the past year, AZN TTM EBITDA has changed by $0.00 (0.00%)